Sanofi (SNY)

Etorro trading 970x250
Sanofi (SNY) Logo

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. Address: 54, Rue La BoEtie, Paris, France, 75008

Sanofi News and around…

Latest news about Sanofi (SNY) common stock and company :

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
25 May, 2022 Yahoo! Finance

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Top Stock Reports for Alphabet, UnitedHealth & Costco
23 May, 2022 Yahoo! Finance

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), UnitedHealth Group Incorporated (UNH), and Costco Wholesale Corporation (COST).

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
23 May, 2022 Yahoo! Finance

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
22 May, 2022 FinancialContent

Biotech stocks advanced in the week endingMay 22, defying the broader market retreat. The defensive nature of the industry and ...

Sanofi Receives Another Approval for Blockbuster Drug Dupixent
20 May, 2022 Yahoo! Finance

The go-ahead covers a chronic inflammatory disease for which the Food and Drug Administration has never before approved a treatment.

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
20 May, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi’s (NASDAQ: SNY) ...

FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
20 May, 2022 Yahoo! Finance

Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date

Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
20 May, 2022 Yahoo! Finance

FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA’s Priority Review action date Dupixent 300 mg weekly significantly improved signs and symptoms of eosinophilic esophagitis compared to placebo in a Phase 3 trial, underscoring the role of type 2 inflammation in this c

UPDATE 2-Sanofi's Dupixent wins U.S. approval for bigger use
20 May, 2022 Yahoo! Finance

Sanofi won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug Administration said on Friday. There are more than 160,000 patients in the United States living with eosinophilic esophagitis (EoE), according to Sanofi. Sanofi's regulatory filing for EoE is under review by the European Medicines Agency, the company said, adding that submissions to regulatory authorities in additional countries are planned by the end of 2022.

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
20 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Recommends COVID-19 ...

This Safe Stock Is Dirt Cheap -- and It's Beating the Market
20 May, 2022 FinancialContent

There's a lot to like about this big pharma juggernaut.

7 Penny Stocks With 10x Potential This Year
17 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward. The post 7 Penny Stocks With 10x Potential This Year appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

How The Parts Add Up: PID Targets $20
17 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco International Dividend Achievers ETF (PID), we found that the implied analyst target price for the ETF based upon its underlying holdings is $20.44 per unit.

Unilever and Sanofi pile on pressure over 2035 EU petrol ban
17 May, 2022 Yahoo! Finance

A cross-sector coalition of companies including Unilever, Zurich, Sanofi and Uber have urged the EU to ban the sale of new petrol and diesel vehicles from 2035, piling pressure on the auto industry ahead of a crunch vote. In a public letter to be sent to MEPs and ministers on Tuesday, the group says such a decision would “set in motion an urgently needed systemic transformation and make Europe a global leader in a key industry”. Volkswagen’s chief executive Herbert Diess has also directly criticised German utility companies in the past, including coal-fired power producers RWE and Uniper, for not doing enough to decarbonise energy.

Sanofi To Pay €400K As Compensation For Epilepsy Drug-Related Side Effects
16 May, 2022 FinancialContent

A French court has orderedSanofi SA(NASDAQ: SNY) to pay more than€400,000in damages to a French family ...

European Dividend Aristocrats: 40 Top International Dividend Stocks
16 May, 2022 Yahoo! Finance

Similar to their American counterparts, the S&P Europe 350 Dividend Aristocrats offer investors dividend hikes and blue-chip stability.

Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients
16 May, 2022 FinancialContent

Sanofi SA(NASDAQ: SNY)shared the latest resultsfrom the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab) in ...

Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
15 May, 2022 Yahoo! Finance

Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy Latest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomideThe median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilz

Sanofi ordered to compensate French family for epilepsy drug side effects
14 May, 2022 Yahoo! Finance

A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmaker failed to inform about known side effects. The link, alongside physical malformation, had also been recognised in a landmark class action ruling in January, which could potentially lead to hundreds of millions of euros in compensation, though Sanofi said it would file an appeal. The latest ruling, made last week and seen by Reuters on Saturday, states that Sanofi must have known the risk that the drug, if taken by pregnant women, could cause malformations and "neuro-behavioural disorders" in children, which should have been mentioned in its attached leaflet.

Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
13 May, 2022 FinancialContent

Arkansas has accusedEli Lilly And Co(NYSE: LLY),Novo Nordisk A/S(NYSE: NVO),Sanofi SA(NASDAQ: ...

DRIO: First Quarter 2022 Financial and Operational Results
13 May, 2022 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT On May 12, 2022, DarioHealth Corp. (NASDAQ:DRIO) published its first quarter 2022 operational and financial results and filed its Form 10-Q for the three month period ending March 31, 2022. Dario hosted a conference call and webcast to discuss results in further detail. During the quarter, 14 new business to business (B2B)

Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
13 May, 2022 FinancialContent

The story around psychedelic medicine continues to get bigger.

Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
12 May, 2022 Yahoo! Finance

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.

How Novo Nordisk Will Protect Insulin Sales
12 May, 2022 FinancialContent

Advancing insulin technology promises a better patient experience.

Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)
11 May, 2022 FinancialContent

Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it’s Q1 report. Some of it’s shortfall was ...

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
11 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Veru Suggested By FDA To ...

Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
11 May, 2022 FinancialContent

Sanofi SA(NASDAQ: SNY) andAstraZeneca plc(NASDAQ: AZN) have announced results from a prespecified pooled analysis ...

Heart Failure Treatment Offers Hope to Diabetics
11 May, 2022 FinancialContent
7 Biotech Stocks With Key Catalysts for May
11 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Press Release: New nirsevimab data analyses reinforce efficacy against RSV
11 May, 2022 Yahoo! Finance

New nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single doseTwo analyses are being presented at the European Society for Paediatric Infecti

Sanofi (SNY) is a NASDAQ Common Stock listed in , ,

970x250